The trial, which is the largest of its kind, showed that short-term statin treatment did not benefit heart surgery patients and increased the risk of developing kidney damage. These results, published today in the New England Journal of Medicine (NEJM), rule out a clinical benefit of the rapid anti-inflammatory and antioxidant effect of statin therapy in heart surgery and are expected to change international guidelines on preventing AF and other in-hospital complications after heart surgery (1).
However, the findings do not challenge the strong evidence that long-term treatment with statins reduces heart attack and stroke risk by lowering the levels of ‘bad’ LDL cholesterol in the blood (2).
Atrial fibrillation is an increasingly common heart rhythm disorder. Over 1.1 million people in the UK have been diagnosed with AF and hundreds of thousands more are estimated to be undiagnosed (3). AF can cause palpitations (being aware of your heart beat), tiredness, dizziness or feeling faint, and shortness of breath. But the major concern with AF is that it increases the risk of a stroke by around four to five times (4). AF is a frequent complication of cardiac surgery. Current guidelines recommend a short course of statins to prevent the development of AF (5), but the evidence to support this practice is limited.
The Statin Therapy In Cardiac Surgery (STICS) trial, led by BHF Professor Barbara Casadei at the University of Oxford, involved randomly giving 1,922 people scheduled for heart surgery either a daily dose of a statin (rosuvastatin 20 mg daily) or a matching placebo tablet. These people had a normal heart rhythm, so did not have AF before surgery, and received their tablets for up to eight days before surgery and for five days afterwards.
The heart patients were recruited and treated in China at the Fuwai Hospital. Patient randomisation and analysis of the data and samples collected was carried out in Oxford. Alongside the BHF, the trial was funded by the European Network for Translational Research in Atrial Fibrillation of the European Commission Seventh Framework Program, the NIHR Oxford Biomedical Research Centre (BRC), and the Medical Research Council (MRC) and by a small unrestricted grant from AstraZeneca.
The researchers confirmed that the concentration of C-reactive protein (an indication of inflammation) was lower in the patients taking the statin for a just a few days than in those taking the placebo. But the rates of AF after surgery were not significantly different between the two groups of patients (21.1 per cent with statin vs. 20.5 per cent with placebo). The levels of the protein troponin I in the blood, which indicates heart damage, were also not significantly different between the patients taking the statin and those taking the placebo.
As well as showing no benefits, short-term statin treatment in these patients caused an increase in the rate of acute kidney injury after surgery (24.7 per cent with statin vs. 19.3 per cent with placebo).
BHF Professor Barbara Casadei, who led the research at the University of Oxford and is a consultant cardiologist at the John Radcliffe Hospital, said:
“Statins have been known to have rapid anti-inflammatory and antioxidant effects for many years. It was important to establish whether such effects would translate into patient benefit in conditions accompanied by a strong inflammatory response, such as heart surgery.
“Although guidelines currently recommend statins at the time of heart surgery to reduce complications, the evidence was not very strong. The results of our large randomised placebo-controlled trial conclusively prove that there are no benefits to taking statins shortly before and after heart surgery to reduce postoperative complications but there is an adverse effect on kidney function.
“As a doctor I want to do everything I can to ensure my patients get the best possible care and minimise any complications that can come from a heart operation. Unfortunately we now know that statins are not the right treatment to minimise AF and heart damage after surgery. We expect these results to rapidly change guidelines around the world to ensure patients receive the best evidence-based care.”
Professor Peter Weissberg, Medical Director at the British Heart Foundation, which helped fund the research, said:
“A clinical trial that shows that a drug is ineffective is as important as one that demonstrates benefit. Large, properly conducted clinical trials like this are vital for providing the robust evidence needed to show which treatments are safest and most effective and to inform clinical guidelines.
"This study clearly shows that statins should not be given to patients at the time of heart surgery in an attempt to reduce complications like AF. But the study does not negate the wealth of evidence showing that long-term statin treatment reduces the risk of future heart attacks and strokes.
“The BHF continues to fund research into reducing the complications from surgery and, with BHF support, Professor Casadei is finding better ways to manage AF. We urgently need better ways of preventing this dangerous heart rhythm disorder that can lead to strokes, and research is helping us to find them.”
Find out how donations to the BHF fight heart disease through research at bhf.org.uk/research
ENDS
To request interviews or for more information please call the BHF press office on 020 7554 0164 or 07764 290 381 (out of hours) or email [email protected]
Notes to editors
1) Zheng Z., Jayaram R., Jiang L., et al. Perioperative Rosuvastatin in Cardiac Surgery. The New England Journal of Medicine 2016; 374:1744-53. DOI: 10.1056/NEJMoa1507750. PDF download available for media use only (do not distribute or share this link) at https://we.tl/Eid6ddKfJZ (link expires 10 May 2016)
2) More information about statins: https://www.bhf.org.uk/heart-health/treatments/statins
3) Cardiovascular disease statistics 2015, BHF. Available at https://www.bhf.org.uk/statistics
4) More information about AF: https://www.bhf.org.uk/heart-health/conditions/atrial-fibrillation
5) See references 19-21 of “Perioperative Rosuvastatin in Cardiac Surgery” (see reference 1 above).
British Heart FoundationCoronary heart disease is the UK’s single biggest killer. For over 50 years we’ve pioneered research that’s transformed the lives of people living with heart and circulatory conditions. Our work has been central to the discoveries of vital treatments that are changing the fight against heart disease. But so many people still need our help. From babies born with life-threatening heart problems to the many Mums, Dads and Grandparents who survive a heart attack and endure the daily battles of heart failure. Every pound raised, minute of your time and donation to our shops will help make a difference to people’s lives. Find out more at bhf.org.uk
The University of Oxford’s Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK’s top-ranked medical school. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery. A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
The NIHR Oxford Biomedical Research Centre is funded by the National Institute for Health Research, and is a partnership between the Oxford University Hospitals NHS Foundation Trust and the University of Oxford. The NIHR provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university), and conducting leading edge research focused on the needs of patients.
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. The NIHR is the research arm of the NHS. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).
The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. www.mrc.ac.uk
RSS